ArticlePain and therapy2026
Post Hoc Analysis of Time to First and Sustained Improvement in Weekly Migraine Days Among Patients Receiving Preventive Treatment With Rimegepant 75 mg.
Article in Pain and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03732638 (A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFor preventive migraine treatment, understanding an intervention's onset, extent of action, and duration can help set realistic treatment expectations and may help prevent both premature discontinuation and reduce unnecessary prolonged exposure. Rimegepant is an oral calcitonin gene-related peptide receptor (CGRP) antagonist with demonstrated efficacy in the acute and preventive treatment of migraine. This post hoc analysis aimed to assess the onset of benefits of rimegepant 75 mg for the preventive treatment of migraine.
methodsMedian (25th, 75th percentiles) time to first and sustained reductions in weekly migraine days (WMDs) were estimated. Improvements from baseline were evaluated in 10% increments. Time to first improvement was based on the first week that a reduction of a particular magnitude was achieved, and time to sustained improvement was defined as the week that a reduction at a particular level was achieved and that persisted, on average, until study end.
resultsAmong 370 participants, the median (25th, 75th percentiles) time to first reduction in WMDs of ≥ 50% was 2 (1, 4) weeks. Thus, 50% of patients are expected to experience ≥ 1 week with a ≥ 50% reduction in WMDs within the first 2 weeks. The median (25th, 75th percentiles) time to a sustained reduction in WMDs of ≥ 50% was 3 (1, 14) weeks. Accordingly, 50% of patients are expected to experience a ≥ 50% reduction in WMDs by week 3 and to maintain this improvement, on average, up to week 64.
conclusionFollowing rimegepant 75-mg treatment initiation, it is expected that 50% of patients will experience first ≥ 50% reduction in WMDs by week 2 and sustained reduction by week 3. Graphical abstract available for this article. CLINICAL
trial registrationClinicalTrials.gov number: NCT03732638. https://www. CLINICALTRIALS: gov/study/NCT03732638 .
Indexed as
Identifiers
42816745What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.